Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery
The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in.
Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal
The companies intend to develop Burning Rock's 168-gene OncoCompass Target test as a companion to Merck's MET inhibitor Tepmetko in mainland China.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.